Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Cash from Investing Activities (2016 - 2022)

Historic Cash from Investing Activities for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Q4 2022 value amounting to $22.9 million.

  • Avadel Pharmaceuticals' Cash from Investing Activities rose 4931.46% to $22.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $79.7 million, marking a year-over-year increase of 3999.54%. This contributed to the annual value of $51.8 million for FY2024, which is 20336.77% up from last year.
  • According to the latest figures from Q4 2022, Avadel Pharmaceuticals' Cash from Investing Activities is $22.9 million, which was up 4931.46% from $2.5 million recorded in Q3 2022.
  • Avadel Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $42.3 million during Q1 2022, with a 5-year trough of -$80.9 million in Q2 2020.
  • Its 5-year average for Cash from Investing Activities is $3.4 million, with a median of $11.6 million in 2021.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first skyrocketed by 315216.57% in 2018, then crashed by 100418.06% in 2020.
  • Quarter analysis of 5 years shows Avadel Pharmaceuticals' Cash from Investing Activities stood at $16.2 million in 2018, then tumbled by 68.1% to $5.2 million in 2019, then surged by 40.06% to $7.2 million in 2020, then soared by 111.57% to $15.3 million in 2021, then soared by 49.31% to $22.9 million in 2022.
  • Its last three reported values are $22.9 million in Q4 2022, $2.5 million for Q3 2022, and $12.0 million during Q2 2022.